1. Pink Sheet

Battlefield Emergency Use Bill Faces Pushback From US FDA, Authorizing Committees

 
• By Michael Cipriano

Top Republicans on FDA authorizing committees worry that undermining agency's sole authority to approve drugs and devices would bring more harm than good.

Battlefield medicine
• Source: US Navy photo by Mass Communication Specialist 2nd Class Summer Anderson

The US FDA's congressional authorizing committees have joined a growing chorus of opposition against the Department of Defense (DOD) budgetary bill that would allow the department to approve medical products for the battlefield setting, the sponsors of which argue FDA is taking too long in this area.

Section 731 of H.R. 2810, the annual defense spending policy bill known as the National Defense Authorization Act (NDAA) specifically would allow DOD to authorize the emergency use of an...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Legislation

More from Pink Sheet

EU To Track Decentralized Clinical Trials In CTIS To Support Innovation

 
• By Vibha Sharma

Monitoring the use of decentralized elements in clinical trials is a priority for the European medicines regulatory network.

Why Hympavzi Secured English Funding For Hemophilia B But Not Hemophilia A

 
• By Neena Brizmohun

Pfizer told the Pink Sheet it would work with the health technology assessment institute, NICE, with the hope of making Hympavzi available to patients with hemophilia A via the National Health Service.

Autolus’s Aucatzyl And GSK’s Blenrep Among 10 New Drugs To Get EMA Nod

 
• By Vibha Sharma

The European Medicines Agency has OKd 10 new medicines for EU-wide approval, including a CAR-T therapy for treating acute lymphoblastic leukemia. Two drugs were, however, rejected.